Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments

NCT06218511 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT06218511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06218511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 22, 2022
Completion date
November 30, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma